CURXHealthcare · BiotechnologyCURX Stock Forecast: Curanex Pharmaceuticals, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 5 of 100 as at 22 Aug 2026 — in the weakest quartile.
CURX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Curanex Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Momentum (1): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
CURX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CURX, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CURX appears on the weeks it earns a place.
CURX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Curanex Pharmaceuticals, Inc. (CURX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.4×
- Price / sales
- —
- Price / book
- 27.9×
- EV / EBITDA
- −35.1×
Cheaper than 84% of US stocks
Cheaper than 4% of US stocks
Cheaper than 92% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −411.1%
- Return on assets
- −225.1%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CURX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Curanex Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about CURX stock
How does Ticker Nerd's model rank CURX?
As at 22 Aug 2026, Curanex Pharmaceuticals, Inc. ranks 5 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
What is the CURX stock forecast for 2030?
No analyst covering Curanex Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CURX are extrapolating price history, which says nothing about the business.
What does Curanex Pharmaceuticals, Inc. do?
Curanex Pharmaceuticals Inc. is a developmental stage biotechnology company focused on the discovery, development, and commercialization of innovative botanical drugs.
About Curanex Pharmaceuticals, Inc.
Curanex Pharmaceuticals Inc. is a developmental stage biotechnology company focused on the discovery, development, and commercialization of innovative botanical drugs. Its primary mission is to address significant unmet medical needs by leveraging natural substances, aiming to improve the lives of patients with immune and inflammatory diseases. The company dedicates its research to creating botanical medicines that may offer therapeutic benefits in fields such as autoimmune conditions, metabolic disorders, and viral infections. Founded in 2018 and headquartered in Jericho, New York, Curanex plays a specialized role within the healthcare sector by targeting novel approaches in the biotechnology industry. Through its developmental pipeline, Curanex seeks to expand therapeutic options where conventional pharmaceuticals may be insufficient, positioning itself at the intersection of natural product research and modern drug development. The company operates in a market environment that values innovation for difficult-to-treat medical conditions, reflecting its commitment to both clinical advancement and addressing gaps in standard care.
CEO Mr. Jun Liu · 6 employees · United States · https://www.curanexpharma.com